Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: Implications for glutamatergic and dopaminergic model psychoses and cognitive function

Archives of General Psychiatry

Volumn 62, Issue 9, 2005, Pages 985-995

  Krystal, John H ^a,b,c   Perry Jr , Edward B ^a,b,c   Gueorguieva, Ralitza ^a,c   Belger, Aysenil ^a,b,g   Madonick, Steven H ^d   Abi Dargham, Anissa ^e   Cooper, Thomas B ^e   MacDougall, Lisa ^a,b,c   Abi Saab, Walid ^f   Cyril D'Souza, D ^a,b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Yale University School of Medicine   (United States)

^d INSTITUTE OF LIVING   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f ABBOTT LABORATORIES   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; SODIUM CHLORIDE;

ADULT; AROUSAL; ARTICLE; COMMUNITY; CONTROLLED STUDY; DRUG EFFECT; EUPHORIA; FEMALE; HOSTILITY; HUMAN; MALE; NORMAL HUMAN; PSYCHOPHARMACOLOGY; RANDOMIZATION; RECALL; SYMPTOM; THOUGHT DISORDER;

AMPHETAMINE; COGNITION; DOPAMINE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; GLUTAMINE; HUMANS; KETAMINE; PLACEBOS; PREFRONTAL CORTEX; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 24344462681     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.62.9.985     Document Type: Article

References (72)

1. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol. 2001;41:237-260.
2. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci. 2003;1003:318-327.
3. Tamminga CA, Lahti AC, Medoff DR, Gao XM, Holcomb HH. Evaluating glutamatergic transmission in schizophrenia. Ann N Y Acad Sci. 2003;1003:113-118.
4. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron. 2003;40:881-884.
5. LaruelleM, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci. 2003;1003:138-158.
6. Meador-Woodruff JH, Clinton SM, Beneyto M, McCullumsmith RE. Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia. Ann N Y Acad Sci. 2003;1003:75-93.
7. Konradi C, Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther. 2003;97:153-179.
8. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman RE. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003;169:215-233.
9. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002;7:S71-S80.
10. Chambers RA, Bremner JD, Moghaddam B, Southwick SM, Charney DS, Krystal JH. Glutamate and post-traumatic stress disorder: toward a neurobiology of dissociation. Semin Clin Neuropsychiatry. 1999;4:274-281.
11. Krystal JH, Petrakis IL, Mason G, D'Souza DC. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther. 2003;99:79-94.
12. Kegeles LS, Zea-Ponce Y, Abi-Dargham A, Mann JJ, Laruelle M. Ketamine modulation of amphetamine-induced striatal dopamine release in humans. Biol Psychiatry. 1999;45:20S.
13. Hart CL, Haney M, Foltin RW, Fischman MW. Effects of the NMDA antagonist memantine on human methamphetamine discrimination. Psychopharmacology (Berl). 2002;164:376-384.
14. Krystal JH, Abi-Dargham A, Laruelle M, Moghaddam B. Pharmacologic models of psychosis. In: Charney DS, Nestler EJ, eds. Neurobiology of Mental Illness. 2nd ed. New York, NY: Oxford University Press; 2003:287-298.
15. Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis: preliminary observations. Biol Psychiatry. 1970;2:95-107.
16. Griffith JD, Cavanaugh J, Held J, Oates JA. Dextroamphetamine evaluation of psychotomimetic properties in man. Arch Gen Psychiatry. 1972;26:97-100.
17. Bell DS. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry. 1973;29:35-40.
18. Angrist B, Sathananthan G, Wilk S, Gershon S. Amphetamine psychosis: behavioral and biochemical aspects. J Psychiatr Res. 1974;11:13-23.
19. Janowsky DS, Risch C. Amphetamine psychosis and psychotic symptoms. Psychopharmacology (Berl). 1979;65:73-77.
20. Sherer MA, Kumor KM, Cone EJ, Jaffe JH. Suspiciousness induced by fourhour intravenous infusions of cocaine: preliminary findings. Arch Gen Psychiatry. 1988;45:673-677.
21. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug-Sernyl. Arch Neurol Psychiatry. 1959;81:363-369.
22. Domino EF, Chodoff P, Corssen G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther. 1965;6:279-291.
23. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
24. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996;14:301-307.
25. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Kelly Melson A, Hershey T, Craft S, Olney JW. Ketamine-induced NMDA receptor hypofunction as model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20:106-118.
26. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997;7:25-38.
27. Rosse RB, Collins JR Jr, Fay-McCarthy M, Alim TN, Wyatt RJ, Deutsch SI. Phenomenologic comparison of the idiopathic psychosis of schizophrenia and druginduced cocaine and phencyclidine psychoses: a retrospective study. Clin Neuropharmacol. 1994;17:359-369.
28. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A. 1996;93:9235-9240.
29. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A. 1997;94:2569-2574.
30. Chuhma N, Zhang H, Masson J, Zhuang X, Sulzer D, Hen R, Rayport S. Dopamine neurons mediate a fast excitatory signal via their glutamatergic synapses. J Neurosci. 2004;24:972-981.
31. Joyce MP, Rayport S. Mesoaccumbens dopamine neuron synapses reconstructed in vitro are glutamatergic. Neuroscience. 2000;99:445-456.
32. Takahata R, Moghaddam B. Glutamatergic regulation of basal and stimulusactivated dopamine release in the prefrontal cortex. J Neurochem. 1998;71:1443-1449.
33. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R-Non-Patient Edition (SCID-NP, Version 1.0 With Supplement for DSM-IV). Washington, DC: American Psychiatric Press; 1990.
34. Chapman LJ, Edell WS, Chapman JP. Physical anhedonia, perceptual aberration, and psychosis proneness. Schizophr Bull. 1980;6:639-653.
35. Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC. Putatively psychosisprone subjects 10 years later. J Abnorm Psychol. 1994;103:171-183.
36. Bell M, Billington R, Becker B. A scale for the assessment of object relations: reliability, validity, and factorial invariance. J Clin Psychol. 1986;42:733-741.
37. Cho HS, D'Souza DC, Gueorguieva R, Perry EB, Madonick S, Karper LP, Abi-Dargham A, Belger A, Abi-Saab W, Lipschitz D, Bennet A, Seibyl JP, Krystal JH. Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology (Berl). 2005;179:136-143.
38. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989;7:59-67.
39. Bell MD, Lysaker PH, Beam-Goulet JL, Milstein RM, Lindenmayer JP. Fivecomponent model of schizophrenia: assessing the factorial invariance of the Positive and Negative Syndrome Scale. Psychiatry Res. 1994;52:295-303.
40. Gordon M. Gordon Diagnostic Systems. DeWitt, NY: Gordon Systems; 1983.
41. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5:125-142.
42. Reimer MLJ, Mamer OA, Zavitsanos AP, Siddiqui AW, Dadgar D. Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. Biol Mass Spectrom. 1993;22:235-242.
43. Brunner E, Domhof S, Langer F. Nonparametric Analysis of Longitudinal Data in Factorial Experiments. New York, NY: John Wiley & Sons; 2002.
44. Brown H, Prescott R. Applied Mixed Models in Medicine. West Sussex, England: John Wiley & Sons; 1999.
45. Øye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992;260:1209-1213.
46. Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry. 1998;55:354-360.
47. Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L, D'Souza DC. NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. Ann N Y Acad Sci. 2003;1003:176-184.
48. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 1991;251:947-950.
49. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 1995;376:572-575.
50. Lisman JE, Fellous J-M, Wang X-J. A role for NMDA-receptor channels in working memory. Nat Neurosci. 1998;1:273-276.
51. Wang XJ. Synaptic basis of cortical persistent activity: the importance of NMDA receptors to working memory. J Neurosci. 1999;19:9587-9603.
52. Durstewitz D, Seamans JK. The computational role of dopamine D1 receptors in working memory. Neural Netw. 2002;15:561-572.
53. Cai JX, Arnsten AF. Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J Pharmacol Exp Ther. 1997;283:183-189.
54. Zahrt J, Taylor JR, Mathew RG, Arnsten AF. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci. 1997;17:8528-8535.
55. Sawaguchi T, Goldman-Rakic PS. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol. 1994;71:515-528.
56. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A. 2003;100:6186-6191.
57. Arnsten AF. Stress impairs prefrontal cortical function in rats and monkeys: role of dopamine D1 and norepinephrine alpha-1 receptor mechanisms. Prog Brain Res. 2000;126:183-192.
58. Birnbaum SG, Podell DM, Arnsten AF. Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000;67:397-403.
59. Williams GV, Rao SG, Goldman-Rakic PS. The physiological role of 5-HT2A receptors in working memory. J Neurosci. 2002;22:2843-2854.
60. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci. 2002;22:3708-3719.
61. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry. 2000;48:627-640.
62. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921-2927.
63. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors: implications for models of schizophrenia. Mol Psychiatry. 2002;7:837-844.
64. Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard P. Diverse psychotomimetics act through a common signaling pathway. Science. 2003;302:1412-1415.
65. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner JD, Bowers MB Jr, Suckow RF, Stetson P, Heninger GR, Charney DS. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl). 1998;135:213-229.
66. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB Jr, Vegso S, Heninger GR, Charney DS. Interactive effects of subanesthetic ketamine and haloperidol. Psychopharmacology (Berl). 1999;145:193-204.
67. Anand A, Charney DS, Cappiello A, Berman RM, Oren DA, Krystal JH. Lamotrigine attenuates ketamine effects in humans: support for hyperglutamatergic effects of NMDA antagonists. Arch Gen Psychiatry. 2000;57:270-276.
68. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry. 1997;42:664-668.
69. Greenberg BD, Segal DS. Acute and chronic behavioral interactions between phencyclidine (PCP) and amphetamine: evidence for a dopaminergic role in some PCPinduced behaviors. Pharmacol Biochem Behav. 1985;23:99-105.
70. Moghaddam B, Bolinao ML. Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release. Synapse. 1994;18:337-342.
71. Kegeles LS, Martinez D, Kochan LD, Hwang DR, Huang Y, Mawlawi O, Suckow RF, Van Heertum RL, Laruelle M. NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse. 2002;43:19-29.
72. Carlezon WA Jr, Wise RA. Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J Neurosci. 1996;16:3112-3122.